source
- Precision strategies help de-risk rare disease therapy launchesCommercializing a rare disease therapy presents a high‑risk, high‑reward scenario for biotech firms. Small patient populations, stringent regulatory requirements, and the need to sustain value beyo…
- Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffersAs always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.Fierce Biotech · 8mo ago↗ source
- Fierce Biotech Fundraising Tracker '26: Abcuro secures $66M; InduPro assembles $77MThe Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.